# Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

> **NCT06798909** · PHASE3 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 360 (estimated)

## Conditions studied

- Cytomegalovirus (CMV)
- Kidney Transplant; Complications
- Kidney Diseases

## Interventions

- **DRUG:** Valganciclovir (Pre-emptive CMV Therapy)
- **DRUG:** Valganciclovir CMV Prophylaxis

## Key facts

- **NCT ID:** NCT06798909
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2030-11-30
- **Final completion:** 2031-05-31
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06798909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06798909, "Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06798909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*